DDInter1158 DDInter1355
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin&reg;.
Mesalazine {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Nabumetone
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Picosulfuric acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Mesalazine (Compound) binds MPO (Gene) and MPO (Gene) is bound by Oxaliplatin (Compound)
Mesalazine (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) binds MPO (Gene) and MPO (Gene) is bound by Nabumetone (Compound) and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) resembles Dopamine (Compound) and Dopamine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin